NGeneBio Co

NGeneBio Co Net Tangible Assets

The Net Tangible Assets of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 19.98 B KRW. In the previous year, Net Tangible Assets was 9.16 B KRW — a change of 118.11% (higher).

Net Tangible Assets

19.98 BKRW

YoY

118.11%

Last updated:

Net Tangible Assets of NGeneBio Co is 2025 19.98 B KRW. Net Tangible Assets of NGeneBio Co was 2024 9.16 B KRW. It decreases by 118.11% higher compared to the previous year.

The NGeneBio Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
-3.21 B KRW
Jan 1, 2019
3.29 B KRW
Jan 1, 2020
41.12 B KRW
Jan 1, 2021
32.33 B KRW
Jan 1, 2022
23.66 B KRW
Jan 1, 2023
14.42 B KRW
Jan 1, 2024
9.16 B KRW
Jan 1, 2025
19.98 B KRW
The NGeneBio Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
19.98 BKRW+118.11%
9.16 BKRW-36.48%
14.42 BKRW-39.03%
23.66 BKRW-26.84%
32.33 BKRW-21.36%
41.12 BKRW+1,150.59%
3.29 BKRW-202.44%
-3.21 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Net Tangible Assets of NGeneBio Co is 19.98 B KRW in 2025.

Net Tangible Assets of NGeneBio Co changed from 9.16 B KRW to 19.98 B KRW, representing a 118.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's NGeneBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NGeneBio Co

All Key Metrics — NGeneBio Co